Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Miksad

GI Oncology · BMC

View

Dr. Colin Weekes

GI Oncology · MGH

View

Dr. Elizabeth Jaffee

GI Oncology · Johns Hopkins

View

Dr. Aparna Parikh

GI Oncology · PHS

View

Dr. Laura Vater

GI Oncology · IUSM

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    HEDr. Haley Ellis

    Dr. Haley Ellis

    Medical Oncology · Gastrointestinal Oncology
    Massachusetts General Hospital
    haley

    Research

    Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib

    2026

    Via Annals of Oncology

    Research

    Genomic Landscape of Clinically Acquired Resistance Alterations in Patients Treated with KRAS Inhibitors

    2025

    Via Annals of Oncology

    Research

    Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets

    2025

    Via Cancer Discovery

    Research

    Diagnostic Performance of PSMA PET/MRI in Characterizing LI-RADS 3 Observations in Patients with Cirrhosis

    2025

    Via Journal of Nuclear Medicine

    Research

    MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response

    2025

    Via Clinical Cancer Research

    Research

    Allosteric PI3K-alpha Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

    2024

    Via Cancer Discovery

    Research

    FGFR Inhibition Blocks NF-kB-Dependent Glucose Metabolism and Confers Metabolic Vulnerabilities in Cholangiocarcinoma

    2024

    Via Nature Communications

    Research

    FGFR inhibition blocks NF-κB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

    2024

    Via Nature Communications

    Research

    Generation of a Biliary Tract Cancer Cell Line Atlas Reveals Molecular Subtypes and Therapeutic Targets

    2024

    Via bioRxiv

    Research

    Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

    2024

    Via Cancer Discovery

    Research

    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

    2024

    Via Clinical Cancer Research

    Research

    FGFR inhibition blocks NF-kB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

    2024

    Via Nature Communications

    Research

    Allosteric PI3Kα Inhibition Overcomes On-Target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

    2024

    Via Cancer Discovery

    Research

    Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

    2024

    Via Clinical Cancer Research

    Research

    Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?

    2024

    Via JCO Precision Oncology